CytomX Therapeutics, Inc. (CTMX)

Name: CytomX Therapeutics, Inc. (CTMX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001501989 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, CytomX Therapeutics, Inc. reported revenue of $76.20M. Revenue fell 44.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $18.30M.

Key ratios (year ended 2025-12-31)

-29.3%

Operating margin

-22.8%

Net margin

-17.5%

Return on year-end equity

-44.8%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4/A (ownership change) · 2026-10-16

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30
Revenue	$18.30M	$76.20M	$138.10M	$101.21M	$53.16M	n/a	n/a	n/a	$37.31M	n/a	n/a
R&D Expense	$73.38M	$68.73M	$83.38M	$77.68M	$111.65M	n/a	n/a	n/a	$114.19M	n/a	n/a
Operating Income	-$87.15M	-$22.36M	$25.00M	-$6.48M	-$101.33M	n/a	n/a	n/a	-$116.04M	n/a	n/a
Net Income	-$79.65M	-$17.37M	$31.87M	-$569.0K	-$99.32M	n/a	n/a	n/a	-$115.87M	n/a	n/a
Total Assets	$381.23M	$151.57M	$120.53M	$201.79M	$260.89M	n/a	n/a	n/a	$339.41M	n/a	n/a
Total Liabilities	$79.16M	$52.56M	$120.99M	$249.24M	$346.64M	$307.03M	$314.62M	$326.56M	$339.87M	$340.80M	$344.33M
Shareholders' Equity	$302.07M	$99.01M	-$456.0K	-$47.45M	-$85.75M	-$80.54M	-$54.54M	-$29.74M	-$459.0K	$30.43M	$58.11M
Cash & Equivalents	$17.22M	$12.67M	$38.05M	$17.17M	$193.65M	n/a	n/a	n/a	$205.53M	n/a	n/a
Operating Cash Flow	-$82.41M	-$75.59M	-$86.23M	-$56.03M	-$110.79M	n/a	n/a	n/a	-$119.03M	n/a	n/a
Capital Expenditures	$74.0K	$220.0K	$310.0K	$840.0K	$1.74M	n/a	n/a	n/a	$1.61M	n/a	n/a
Free Cash Flow	-$82.48M	-$75.81M	-$86.54M	-$56.88M	-$112.53M	n/a	n/a	n/a	-$120.64M	n/a	n/a
Shares Outstanding	n/a	170.19M	80.10M	67.31M	66.23M	n/a	n/a	n/a	65.39M	n/a	n/a
Weighted Average Diluted Shares	n/a	137.94M	84.75M	73.81M	65.74M	n/a	n/a	n/a	64.15M	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView